The prognostic significance of the aberrant extremes of p53 immunophenotypes in breast cancer. Issue 3 (16th April 2014)
- Record Type:
- Journal Article
- Title:
- The prognostic significance of the aberrant extremes of p53 immunophenotypes in breast cancer. Issue 3 (16th April 2014)
- Main Title:
- The prognostic significance of the aberrant extremes of p53 immunophenotypes in breast cancer
- Authors:
- Boyle, David P
McArt, Darragh G
Irwin, Gareth
Wilhelm‐Benartzi, Charlotte S
Lioe, Tong F
Sebastian, Elena
McQuaid, Stephen
Hamilton, Peter W
James, Jacqueline A
Mullan, Paul B
Catherwood, Mark A
Harkin, D Paul
Salto‐Tellez, Manuel - Abstract:
- <abstract abstract-type="main" id="his12398-abs-0001"> <title> <x xml:space="preserve">Abstract</x> </title> <sec id="his12398-sec-0001" sec-type="section"> <title>Aims</title> <p>The utility of p53 as a prognostic assay has been elusive. The aims of this study were to describe a novel, reproducible scoring system and assess the relationship between differential p53 immunohistochemistry (IHC) expression patterns, <italic>TP53</italic> mutation status and patient outcomes in breast cancer.</p> </sec> <sec id="his12398-sec-0002" sec-type="section"> <title>Methods and results</title> <p>Tissue microarrays were used to study p53 IHC expression patterns: expression was defined as extreme positive (EP), extreme negative (EN), and non‐extreme (NE; intermediate patterns). Overall survival (OS) was used to define patient outcome. A representative subgroup (<italic>n</italic> = 30) showing the various p53 immunophenotypes was analysed for <italic>TP53</italic> hotspot mutation status (exons 4–9). Extreme expression of any type occurred in 176 of 288 (61%) cases. As compared with NE expression, EP expression was significantly associated (<italic>P</italic> = 0.039) with poorer OS. In addition, as compared with NE expression, EN expression was associated (<italic>P</italic> = 0.059) with poorer OS. Combining cases showing either EP or EN expression better predicted OS than either pattern alone (<italic>P</italic> = 0.028). This combination immunophenotype was significant in univariate<abstract abstract-type="main" id="his12398-abs-0001"> <title> <x xml:space="preserve">Abstract</x> </title> <sec id="his12398-sec-0001" sec-type="section"> <title>Aims</title> <p>The utility of p53 as a prognostic assay has been elusive. The aims of this study were to describe a novel, reproducible scoring system and assess the relationship between differential p53 immunohistochemistry (IHC) expression patterns, <italic>TP53</italic> mutation status and patient outcomes in breast cancer.</p> </sec> <sec id="his12398-sec-0002" sec-type="section"> <title>Methods and results</title> <p>Tissue microarrays were used to study p53 IHC expression patterns: expression was defined as extreme positive (EP), extreme negative (EN), and non‐extreme (NE; intermediate patterns). Overall survival (OS) was used to define patient outcome. A representative subgroup (<italic>n</italic> = 30) showing the various p53 immunophenotypes was analysed for <italic>TP53</italic> hotspot mutation status (exons 4–9). Extreme expression of any type occurred in 176 of 288 (61%) cases. As compared with NE expression, EP expression was significantly associated (<italic>P</italic> = 0.039) with poorer OS. In addition, as compared with NE expression, EN expression was associated (<italic>P</italic> = 0.059) with poorer OS. Combining cases showing either EP or EN expression better predicted OS than either pattern alone (<italic>P</italic> = 0.028). This combination immunophenotype was significant in univariate but not multivariate analysis. In subgroup analysis, six substitution exon mutations were detected, all corresponding to extreme IHC phenotypes. Five missense mutations corresponded to EP staining, and the nonsense mutation corresponded to EN staining. No mutations were detected in the NE group.</p> </sec> <sec id="his12398-sec-0003" sec-type="section"> <title>Conclusions</title> <p>Patients with extreme p53 IHC expression have a worse OS than those with NE expression. Accounting for EN as well as EP expression improves the prognostic impact. Extreme expression positively correlates with nodal stage and histological grade, and negatively with hormone receptor status. Extreme expression may relate to specific mutational status.</p> </sec> </abstract> … (more)
- Is Part Of:
- Histopathology. Volume 65:Issue 3(2014)
- Journal:
- Histopathology
- Issue:
- Volume 65:Issue 3(2014)
- Issue Display:
- Volume 65, Issue 3 (2014)
- Year:
- 2014
- Volume:
- 65
- Issue:
- 3
- Issue Sort Value:
- 2014-0065-0003-0000
- Page Start:
- 340
- Page End:
- 352
- Publication Date:
- 2014-04-16
- Subjects:
- Histology, Pathological -- Periodicals
611.018 - Journal URLs:
- http://www.blackwell-synergy.com/member/institutions/issuelist.asp?journal=his ↗
http://onlinelibrary.wiley.com/journal/10.1111/(ISSN)1365-2559 ↗
http://onlinelibrary.wiley.com/ ↗ - DOI:
- 10.1111/his.12398 ↗
- Languages:
- English
- ISSNs:
- 0309-0167
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - 4316.027000
British Library DSC - BLDSS-3PM
British Library HMNTS - ELD Digital store - Ingest File:
- 3971.xml